source
- Eli Lilly expands early-access program for experimental obesity drug retatrutideEli Lilly announced it will broaden its early-access initiative for retatrutide, an investigational drug targeting obesity. The company said the program will let additional patients apply for the…
- Aurora Therapeutics halts its custom CRISPR program and cuts staff after competitor Beam moves aheadAurora Therapeutics, a startup developing personalized gene-editing drugs, announced it is abandoning its lead CRISPR program. The decision came just seven months after the company launched, and i…